Treatment of Heroin Addicts Using Buprenorphine

References

• Cushman P., Dole V. P. Detoxification of methadone maintenance patients. J. Am. Med. Assoc. 1973; 226: 747–751
   PubMed Web of Science ®Google Scholar
• Gold M. S., Redmond D. E., Kleber H. D. Clonidine for opiate withdrawal. Lancet 1978; 1: 929–930
   PubMed Web of Science ®Google Scholar
• Resnick R. B., Kestenbaum R. S., Washton A. Naloxone precipitated withdrawal: A method for rapid induction onto naltrexone. Clin. Pharmacol. Ther. 1977; 21: 409–411
   PubMed Web of Science ®Google Scholar
• Kleber H. D., Riodran C. E., Rounsaville B. J. Clonidine in outpatient detoxification from methadone maintenance. Arch. Gen. Psychiatry 1985; 42: 391–398
   PubMed Web of Science ®Google Scholar
• Kosten T. R., Kleber H. D. Strategies to improve compliance with narcotic antagonists. Am. J. Drug Alcohol Abuse 1984; 10(2)249–266
   PubMed Web of Science ®Google Scholar
• Charney D. S., Redmond D. E., Galloway M. P. Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: Evidence for noradrenergic hyperactivity. life Sci. 1984; 35: 1263–1272
   PubMedGoogle Scholar
• Charney D. S., Riordan C. E., Kleber H. D. Clonidine and naltrexone: A safe effective and rapid treatment of abrupt withdrawal from methadone therapy. Arch. Gen. Psychiatry 1982; 39: 1327–1332
   PubMed Web of Science ®Google Scholar
• Kleber H. D., Topazian M., Gaspari J. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am. J. Drug Alcohol Abuse 1987; 13: 1–18
   PubMed Web of Science ®Google Scholar
• Vining E., Kosten T. R., Kleber H. D. Clinical utility of rapid clonidine naltrexone detoxification for opioid abusers. Br. J. Addict. 1988; 83: 567–575
   PubMedGoogle Scholar
• Woods J. H., Gmerek D. E. Substitution and primary dependence studies in animals. Drug Alcohol Depend 1985; 14: 233–247
   PubMedGoogle Scholar
• Pircio A. W., Gylyl J. A., Cavanagh R. L. The pharmacology of butorphanol, a 3,14-dihydroxymorphinan narcotic antagonist analgesic. Arch. Int. Pharmaco Jyn. Ther. 1976; 220: 231–257
   PubMedGoogle Scholar
• Aceto M. D., Flora R. E., Harris L. S. The effects of naloxone and nalorphine during the development of morphine dependence in rhesus monkeys. Pharmacology 1977; 15: 1–9
   PubMedGoogle Scholar
• Martin W. R., Gorodetzky C. W., McClane T. K. An experimental study in the treatment of narcotic addicts with cyclazocine. Clin. Pharmacol. Ther. 1966; 7: 455–465
   PubMed Web of Science ®Google Scholar
• Jacob J. J. C., Michaud G. M., Tremblay E. C. Mixed agonist-antagonist opiates and physical dependence. Br. J. Clin. Pharmacol 1979; 7: 291s–296s
   Google Scholar
• Nutt J. G., Jasinski D. R. Methadone-naloxone mixtures for use in methadone maintenance programs. I: An evaluation in man of their pharmacological feasibility; II: Demonstration of acute physical dependence. Clin. Pharmacol. Ther. 1973; 15: 156–166
   Google Scholar
• Jasinski D. R., Boren J. J., Henningfield J. E. Progress report from the NIDA Addiction Research Center, Baltimore, MD. Problems of Drug Dependence 1983, L. S. Harris. National Institute on Drug Abuse, Washington, D.C. 1984; 69–76, (Research Monograph 49)
   Google Scholar
• Mello N. K., Mendelson J. H. Buprenorphine suppresses heroin use by heroin addicts. Science 1980; 207: 657–659
   PubMed Web of Science ®Google Scholar
• Jasinski D. R., Pevnick J. S., Griffith J. D. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry 1978; 35: 510–516
   Web of Science ®Google Scholar
• Mello N. K., Mendelson J. H., Kuehnle J. C. Buprenorphine effects on human heroin self-administration: An operate analysis. J. Pharmacol. Exp. Ther. 1982; 223: 30–39
   PubMed Web of Science ®Google Scholar
• Lewis J. W. Buprenorphine. Drug Alcohol Depend 1985; 14: 363–372
   PubMed Web of Science ®Google Scholar
• Dum J. E., Blasig J., Herz A. Buprenorphine: Physical dependence and liability. Eur. J. Pharmacol. 1981; 70: 293–300
   PubMed Web of Science ®Google Scholar
• Wang R. I. H., Weisen R. L., Lamid S. Rating the presence and severity of opiate dependence. Clin. Pharmacol. Ther. 1974; 16: 653–658
   PubMed Web of Science ®Google Scholar
• Kosten T. R., Krystal J. H., Price L. H. Rapid detoxification procedure using buprenorphine. Am. J. Psychiatry, In Press
   Google Scholar
• Kosten T. R., Krystal J. H., Charney D. S. Opioid detoxification using buprenorphine. Proc. Comm Probl. Drug Depend 1988, In Press
   Google Scholar
• Kosten T. R., Kleber H. D., Morgan C. H. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 1989; 44: 887–892
   PubMed Web of Science ®Google Scholar
• Kosten T. R., Kleber H. D., Morgan C. H. Treatment of cocaine abuse with buprenorphine. Biol. Psychiatry, In Press
   Google Scholar
• Hargreaves W. A. Methadone dosage and duration for maintenance treatment. Research on the Treatment of Narcotic Addiction, J. R. Cooper. National Institute on Drug Abuse, Rockville, Maryland 1983; 19–80
   Google Scholar
• Kosten T. R., Kleber H. D. Buprenorphine detoxification from opioid dependence: A pilot study. Life Sci. 1988; 42: 635–641
   PubMed Web of Science ®Google Scholar
• Bickel W. K., Stitzer M. L., Bigelow G. E. Buprenorphine: Dose related blockade of opioid challenge effects in opioid dependent humans. J. Pharmacol. Exp. Ther. 1988; 247: 47–53
   PubMed Web of Science ®Google Scholar
• Kallos T., Smith T. C. Naloxone reversal of pentazocine induced respiratory depression. J. Am. Med. Assoc. 1968; 204: 932
   Google Scholar
• Bickel W. K., Stitzer M. L., Bigelow G. E. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clin. Pharmacol. Ther. 1988; 43: 72–78
   PubMed Web of Science ®Google Scholar